NCT06348927View on ClinicalTrials.gov

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

sunvozertinib in combination with Anlotinib

"Drug: Sunvozertinib combination with Anlotinib~Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle."

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER